Novartis receives green light for five drugs in Japan

Novartis announces that it has received approval from the Japanese authorities for five drugs, namely Tabrecta, Entresto, Mayzent, Enerzair and Atectura.

–

Novartis announced Monday that it has received approval from the Japanese authorities for five drugs, namely Tabrecta, Entresto, Mayzent, Enerzair and Atectura.

The first concerns the treatment during an advanced and / or recurrent positive mutation of lung cancer, the second chronic heart failure, the third the progressive secondary MS (evolution of multiple sclerosis), the fourth and the fifth different forms of asthma.

–